VEGF and MMP-9: biomarkers for canine lymphoma.

Vascular endothelial growth factor (VEGF) and metalloproteinase (MMP) 2 and 9 are useful biomarkers in human lymphoma. During cancerogenesis, transforming growth factor beta (TGF-β) stimulates VEGF and MMPs production. VEGF and TGF-β plasma levels were tested by ELISA, MMP-2 and MMP-9 by gelatine zymography in 37 dogs with lymphoma, 13 of which were also monitored during chemotherapy. Ten healthy dogs served as control. Lymphoma dogs showed higher act-MMP-9 (P < 0.01) and VEGF (P < 0.05), and lower TGF-β than controls, and a positive correlation between act-MMP-9 and VEGF (P < 0.001). Act-MMP-9 and VEGF were significantly higher in T-cell lymphomas, and in stage V compared with stages III-IV disease, regardless of immunophenotype. VEGF was higher in high-grade compared with low-grade T-cell lymphomas. No correlation was found between cytokines levels at presentation and outcome. During chemotherapy, act-MMP-9 and VEGF decreased in B-cell lymphomas (P < 0.01), suggesting a possible predictive role in this group of dogs.

[1]  F. Mutinelli,et al.  Matrix metalloproteinases and their inhibitors in canine mammary tumors , 2011, BMC veterinary research.

[2]  P. Dijke,et al.  The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system , 2011, Breast Cancer Research and Treatment.

[3]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[4]  H. Sakai,et al.  Expression of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Their Receptors (Flt-1, Flk-1, and Flg-1) in Canine Vascular Tumors , 2006, Veterinary pathology.

[5]  H. Johnsen,et al.  Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma , 2005, Annals of Hematology.

[6]  M. Mazzilli,et al.  Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. , 2008, Veterinary immunology and immunopathology.

[7]  F. Zito,et al.  Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model , 2010, Leukemia & lymphoma.

[8]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.

[9]  J. Modiano,et al.  Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionship , 2008, Chromosome Research.

[10]  Tetsuo Himi,et al.  Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non‐Hodgkin lymphoma , 2004, Cancer.

[11]  H. Taniyama,et al.  Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. , 2002, Journal of comparative pathology.

[12]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[13]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[14]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[15]  B. Pasche.  Role of transforming growth factor beta in cancer , 2001, Journal of cellular physiology.

[16]  G. Blobe,et al.  Role of transforming growth factor-beta in hematologic malignancies. , 2006, Blood.

[17]  M. Skalicky,et al.  Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression. , 2008, Research in veterinary science.

[18]  M. J. Ravitz,et al.  Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. , 1997, Advances in cancer research.

[19]  M. Forni,et al.  Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. , 2005, Leukemia research.

[20]  C. Bonnefont,et al.  A Morphological Study of 608 Cases of Canine Malignant Lymphoma in France With a Focus on Comparative Similarities Between Canine and Human Lymphoma Morphology , 2010, Veterinary pathology.

[21]  P. ten Dijke,et al.  Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.

[22]  H. Goldschmidt,et al.  Angiogenesis in hematologic malignancies , 2001, Annals of Hematology.

[23]  K. Chalvet-Monfray,et al.  Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. , 2004, Veterinary journal.

[24]  Pierre Biron,et al.  Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival , 2009, Annals of Hematology.

[25]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[26]  J. Blay,et al.  Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.

[27]  J. Hirschberger,et al.  Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. , 2006, Journal of veterinary internal medicine.

[28]  H. Joensuu,et al.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[29]  J. Taipale,et al.  Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. , 1998, Advances in cancer research.

[30]  E. Macewen,et al.  Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer , 2000, Cancer investigation.

[31]  A. Hanby,et al.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. , 1993, Cancer research.

[32]  M. Shibuya,et al.  The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. , 2005, Clinical science.